News

Biotechs snap up EU money
Enlarge image

FundingBelgiumGermanyIrelandNetherlandsUK

Biotechs snap up EU money

16.04.2013 - Biotechs involved in the bio-economy initiatives of five European countries pool their expertise in an EU project termed BioBaseNWE.

The partners from Bio Base Europe international non-profit organisation (BE), Ghent Bio-Energy Valley (BE), Bio Base Europe Training Center (NL), REWIN/Biobased Innovations (NL), German Cluster Industrielle Biotechnologie, Galway-based Competence Centre for Biorefining and Bioenergy (IRL) and the British National Non-Food Crops Centre (UK) have secured €6.2m from the European Commission.

The overall goal of the Bio Base NWE project is to drive growth and education in the bio-based economy in north-western Europe. The project gets 50% of its €12m overall budget through the INTERREG IVB North West Europe Programme, the other 50% from Agentschap Ondernemen (BE), Biobased delta (NL), Provincie Noord-Brabant (NL), Provincie Zeeland (NL), National University of Ireland NUI Galway, Industrial Development Agency (IDA) Ireland, Enterprise Ireland, and the National Development Plan Ireland. “Bio-based products are a growing area of interest for SMEs working in the chemical industry, agro-industry, plastics, fuels, food, textile and pharma industry“ stressed project manager Lieve Hoflack. „However, many SME’s find it difficult to bridge the gap between newly developed research and the commercial market,” she added.

The network will advise SMEs on how to get financial support for projects at a pilot plant in Ghent. This flexible pilot plant will selectively invest in equipment for promising technologies to promote further growth. The partnership will also develop and deliver programmes and tools for training skilled professionals for bio-based industries.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/biotechs-snap-up-bio-economy-money.html

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON13.90 EUR12.10%
  • MAGFORCE5.10 EUR7.82%
  • SANTHERA103.00 CHF5.64%

FLOP

  • CYTOS0.32 CHF-17.95%
  • CO.DON2.15 EUR-4.44%
  • MEDIGENE3.80 EUR-4.28%

TOP

  • ADDEX3.44 CHF47.6%
  • CYTOS0.32 CHF45.5%
  • FORMYCON13.90 EUR39.1%

FLOP

  • ACTELION100.70 CHF-15.1%
  • MOLOGEN5.72 EUR-13.7%
  • BIOFRONTERA2.02 EUR-12.2%

TOP

  • SANTHERA103.00 CHF2494.5%
  • BB BIOTECH248.45 EUR96.5%
  • FORMYCON13.90 EUR80.5%

FLOP

  • CYTOS0.32 CHF-90.3%
  • 4SC0.82 EUR-50.9%
  • MOLOGEN5.72 EUR-50.8%

No liability assumed, Date: 27.01.2015